GLP-1 implant: overview
- Vivani’s implant delivers semaglutide steadily for up to six months via a membrane rather than injections, with a one-year version in development
- The Novo Nordisk deal is an early evaluation rather than a commercial tie-up – any launch is still years away
- If the implant improves adherence, it could shrink the rebound spending manufacturers have relied on, making the current basket shift more permanent
California biotech company Vivani Medical has signed a non-exclusive agreement allowing Novo Nordisk to evaluate NPM-139, its semaglutide implant.
There’s no licence attached and no exclusivity clause, so this isn’t yet a commercial tie-up, but it’s still a prominent vote of confidence from the company behind Wegovy and Ozempic in a technology built around adherence, not potency.
The implant, built on Vivani’s NanoPortal platform, sits under the skin and releases semaglutide steadily for up to six months, with a one-year version in development, using a membrane threaded with microscopic channels that let the drug diffuse out at a controlled rate.
Vivani says this should avoid the peaks and troughs in blood levels that come with weekly injections, and with them, some of the nausea that drives people off treatment.
Roughly half of all patients on any chronic medication, including daily pills, don’t take it as prescribed, according to Vivani’s own figures, and GLP-1 drop-out is even higher, with some estimates putting it above 50% within a year.
Vivani CEO Adam Mendelsohn said the agreement “reinforces our confidence regarding the market opportunity for our GLP-1 implants under development”, adding that NPM-139 “could address a growing segment of patients who would prefer a convenient once- or twice-yearly treatment option and the peace of mind that treatment could be stopped at any time if that became necessary”.
Take away the weekly jab and you take away the easiest moment for a patient to stop.
Every patient who lapses – whether through cost, side-effects or simply losing the routine of a weekly jab – is a partial reprieve for the categories that have seen a decline due to these drugs. Manufacturers have been relying on that churn to keep the damage to indulgent and discretionary sales from compounding further.
What drop-off has done to spending
Roughly one in eight US adults is currently on a GLP-1 drug, with usage expected to climb further as oral formulations widen access and cost comes down, and analysts have put the potential drag on US food and drink sales as high as $30-$55 billion a year by 2030.
The biggest casualty so far has been anything built around habit and reward rather than nutrition – around seven in 10 users who report eating less say they’re cutting back specifically on impulse and indulgence purchases, with alcohol among the categories showing double-digit declines.
Some researchers believe GLP-1 drugs blunt the brain’s reward response itself, dulling cravings and the low-level ‘food noise’ that drives casual, unplanned eating, rather than simply suppressing appetite at mealtimes.
The spending that remains is moving, not just shrinking. Protein, fibre, fresh categories, yoghurt, lean meat, produce and lower-sugar drinks are all cited repeatedly as beneficiaries, and long-term GLP-1 households are cutting back on everyday pantry staples and dairy basics by more than 10% compared with similar non-user households.
A meaningful share of that spending rebounds, though – patients who lapse tend to hold their new habits for a couple of months before drifting back towards prior purchasing patterns, and it’s this stop-start cycling, more than any single wave of new users, that has kept forecasts of category damage from being worse.
A longer leash changes the maths
Every forecast built on current GLP-1 data assumes a certain amount of natural attrition – patients starting, stopping, restarting, drifting back to old habits in between.
An implant built to extend treatment duration and remove the friction that causes people to lapse doesn’t just add a new format to an already crowded GLP-1 market. If it works as intended, it narrows the cushion that’s kept discretionary spending from falling further, meaning less rebound purchasing and a more permanent version of the basket shift already under way.
The device is years from a pharmacy – if it gets there at all – but the industry’s current planning still assumes that patients drop off. If that assumption weakens, the products and reformulations built to win back share during the ‘off’ months may need to work a good deal harder to earn their place in the basket at all.
